Therefore, anti-HER2 therapy alone may not be adequate treatment for those patients with HER2+ breast cancer harboring a PIK3CA-activating mutation that are associated with a constitutive activation of the PI3K/AKT/mTOR pathway. This evidence concerns the gene MTOR and breast carcinoma.